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Background. Artemether-lumefantrine (AL) is amajor and highly effective artemisinin-based combination ther-
apy that is becoming increasingly important as a new first-line therapy against Plasmodium falciparum malaria.
However, recrudescences occurring after AL treatment have been reported. Identification of drug-specific parasite
determinants that contribute to treatment failures will provide important tools for the detection and surveillance of
AL resistance.
Methods. The findings from a 42-day follow-up efficacy trial in Tanzania that compared AL with sulfadoxine-
pyrimethamine (SP) were analyzed to identify candidate markers for lumefantrine tolerance/resistance in the chlo-
roquine resistance transporter gene (pfcrt) andmultidrug resistance gene 1 (pfmdr1). The findings were corroborated
in vitro with genetically modified isogenic P. falciparum parasite lines.
Results. Treatment with AL selected for the chloroquine-susceptible pfcrt K76 allele (P  .0001) and, to a lesser
extent, the pfmdr1 N86 (P  .048) allele among recurrent infections. These genotypes were not selected during SP
treatment. No pfmdr1 gene amplificationswere observed. Isogenic pfcrt-modified parasite lines demonstrated a 2-fold
increase in susceptibility to lumefantrine, which was directly attributable to the K76T mutation.
Conclusions. Our findings suggest that the pfcrt K76T mutation is a drug-specific contributor to enhanced P.
falciparum susceptibility to lumefantrine in vivo and in vitro, and they highlight the benefit of using AL in areas
affected by chloroquine-resistant P. falciparummalaria.
The development and spread of Plasmodium falciparum
antimalarial drug resistance has spurred a global change
in policy from the use of the former first-line antimalar-
ials chloroquine (CQ) and sulfadoxine-pyrimethamine
(SP) to the use of artemisinin-based combination ther-
apies (ACTs). In 2006, Tanzania changed its drug policy
to the use of artemether-lumefantrine (AL; Coartem
[Novartis]), which is currently the most favored ACT
used in Africa.
AL is highly effective on the African continent [1–3].
Nevertheless, AL has been associated with a relatively
high frequency of reinfection events during the post-
treatment period, when lumefantrine, the longer-lasting
partner drug (with a plasmahalf-life of 4–5 days vs. 3–11
h for artemether), remains in the blood in subtherapeu-
tic concentrations. During this period, selection of less-
susceptible parasites (which have the ability to cause in-
fection in the presence of plasma drug concentrations
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higher than those associated with susceptible parasites causing
infection) may occur.
One gene that has been found to influence susceptibility to
lumefantrine is the P. falciparum multidrug resistance gene 1
(pfmdr1), which encodes a transporter located on the digestive
vacuole (DV) membrane of the erythrocytic stages. Allelic ex-
change experiments with culture-adapted lines, as well as field
studies of clinical isolates, have shown that pfmdr1 single-
nucleotide polymorphisms (SNPs) influence the in vitro re-
sponse to various antimalarial drugs, such as the artemisinin
derivatives and the arylaminoalcohols lumefantrine,mefloquine
(MQ), and halofantrine (HF) [4–7]. An increased pfmdr1
copy number has also been associated with treatment failure
after short 4-dose AL therapy [8], as well as after MQ or
artesunate-MQ therapy [9]. So far, these associations have
been observed only in Southeast Asia. However, an increased
number of pfmdr1 copies has been found in a few patient
samples in Gabon, subsequent to a trial with low-dose MQ
treatment, thereby suggesting the potential of selection of
multicopy pfmdr1 in this region [10]. Hence, the pfmdr1 copy
number may also become important on the African continent
after wide-scale deployment of AL.
Our previous studies in Zanzibar showed that treatment with
AL selected for reinfecting parasites harboring pfmdr1 alleles en-
coding the N86, 184F, and D1246 residues [11, 12]. These find-
ings are consistent with reports from other East African field
sites [13, 14] and suggest the selection of lumefantrine-tolerant
parasites, which may constitute a first step toward full resistance
and associated clinical failure [15]. Nonetheless, it remains un-
clear whether this selection is the result of specific influences on
the drug target or is caused by nonspecific selection of parasites
that are generally more fit and able to thrive in the presence of
environmental stressors. This is an important distinction, con-
sidering that mutations at codons 1034, 1042, and 1246 in
pfmdr1 have been reported to incur fitness costs in vitro [16].
Another question arising from our previous studies is the role
of the chloroquine resistance transporter gene (pfcrt),which en-
codes a transmembrane protein that localizes to the membrane
of the DV and is a key determinant of the chloroquine response
of P. falciparum [17]. The pfcrt K76T mutation has been consis-
tently associatedwithCQ resistance in vitro and in vivo [18–20].
This putative transporter also appears to influence the parasite
response to arylaminoalcohols. Accordingly, mutations at the
pfcrt amino acid 76 position have been suggested to play a role in
MQ susceptibility [19–21]. In addition, in vitro selection of HF
resistance has been associatedwith a novel pfcrt S163Rmutation,
which also has been shown to affect the in vitro response to MQ
[22]. In light of these data, we hypothesized that pfcrt SNPs
might also influence susceptibility to lumefantrine.
To evaluate the influence of pfmdr1 and pfcrtmutations on the
mechanism of resistance to lumefantrine, we searched for selec-
tion of thesemutations in samples collected during a clinical trial
in Fukayosi, Tanzania, in which children with uncomplicated P.
falciparum malaria were treated with AL or SP [2]. SP inhibits
the synthesis of folate by targeting the dihydropteroate syn-
thetase and dihydrofolate reductase enzymes, respectively. This
treatment arm therefore enabled us to test whether any evidence
of selection for pfcrt or pfmdr1mutations in theAL armwas drug
dependent and was not a result of general fitness issues associ-
ated with the parasite response to any antimalarial drug treat-
ment. Furthermore, the availability of isogenic parasites result-
ing from allelic exchange experiments at pfcrt amino acid
position 76 [19, 20] allowed us to evaluate the specific influence
of mutant pfcrt alleles (in particular, the K76T mutation) on the
response of P. falciparum to lumefantrine.
SUBJECTS, MATERIALS, AND METHODS
Subjects. The study was conducted in Fukayosi, Bagamoyo
District, Tanzania, during April–July 2004, as reported else-
where [2]. In brief, 106 children with uncomplicated P. falcipa-
rum malaria were enrolled and randomly allocated to receive
either SP (Fansidar; Roche) or AL (Coartem). Both drugs were
administered according to body weight. Children who were al-
located to receive SP and who had body weights categorized as
5–10 kg, 11–20 kg, and 21–30 kg were given a single dose of
sulfadoxine/pyrimethamine of 250 mg/12.5 mg, 500 mg/25 mg,
and 750 mg/37.5 mg, respectively, whereas children who were
allocated to receive AL and who had body weights categorized as
5–14 kg, 15–24 kg, and 25–34 kg were given a twice-daily dose of
artemether/lumefantrine of 20 mg/120 mg, 40 mg/240 mg, and
60 mg/360 mg, respectively, for 3 days. After enrollment in the
study and initiation of treatment, the childrenwere checked rou-
tinely on days 1, 2, 3, 7, 14, 21, 28, 35, and 42 or on any day of
recurrent illness occurring during the 42-day follow-up. Blood
samples were collected on filter paper (3MM; Whatman) for
molecular analysis. Written informed consent was obtained
from the parents or guardians of the children. The study was
approved by the ethics committees of the Muhimbili University
College of Health and Allied Sciences (Dar Es Salaam, Tanzania)
and Karolinska Institutet (Stockholm, Sweden).
Molecular analysis. DNA was extracted from blood sam-
ples on filter paper by use of the ABI Prism 6100 Nucleic Acid
PrepStation (Applied Biosystems). The status of recurrent in-
fections (recrudescence or reinfection) was available from a pre-
vious study [2] that used stepwise genotyping of the polymor-
phic genetic markers P. falciparum merozoite surface protein
(pfmsp)–2 and –1 to classify treatment outcomes. In the present
study, we analyzed the first baseline day (D0) and the initial day
of recurrent infection (R0).
Mutations in pfmdr1 and pfcrt were investigated to explore
their association with AL tolerance. All infections observed at
baseline were examined, as were all infections that recurred after
AL treatment. The pfmdr1 N86Y and D1246Y SNPs, as well as
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the pfcrt K76T and S163R SNPs, were analyzed by polymerase
chain reaction (PCR) restriction fragment–length polymor-
phism (RFLP) analysis, as described elsewhere [12, 23]. The
pfmdr1 Y184F SNP was assayed using pyrosequencing (Pyro-
Gold Reagents PSQ 96MA and PyroMark MD System; Biotage
AB) with the primer 5'-CCAGTTCCTTTTTAGGTT-3'. The
pfmdr1 S1034C and N1042D SNPs were examined through di-
rect sequencing of PCR products (Macrogen). For infections re-
curring after SP treatment, only the pfmdr1N86Y and pfcrtK76T
mutations were assessed. The pfmdr1 gene copy number was
assessed through the use of TaqMan probe quantitative PCR–
based protocols [12]. All primers were synthesized by Thermo
Electron. RFLP analysis products were separated by electropho-
resis in 2% agarose gels with ethidium bromide and were visu-
alized under UV transillumination (GelDoc System; Bio-Rad).
Statistical analysis. Data from patient samples were ana-
lyzed using GraphPad QuickCalcs software (GraphPad Soft-
ware). Proportions were compared using Fisher’s exact test for
the association of treatment type with SNPs. The complete set of
baseline data (D0 for the AL armD0 for the SP arm) was used
as a common comparator group for both arms of the drug trial.
Statistical significance was denoted by P  .05. When mixed
infections were evaluated, all calculations were performed by
comparing carriers of the selected allele (including pure allele
carriers and mixed infections) with parasites carrying the alter-
native allele in pure form.
P. falciparum propagation in vitro. All parasite lines were
grown at 37°C in human red blood cells at a hematocrit of 3%–
4%, by use of RPMI 1640 medium supplemented with 0.5%
Albumax, 0.25% sodium bicarbonate, and 0.01 mg/mL genta-
micin. Cultures were maintained in an atmosphere of 90% N2,
5% O2, and 5% CO2.
In vitro drug assays. Parasite susceptibilities to lumefan-
trine weremeasured in vitro using 72-h 3H-hypoxanthine assays
with serial drug dilutions, as described elsewhere [24]. IC50 and
IC90 values were determined by linear extrapolation. For statis-
tical analyses, 2-tailed unpaired Student’s t tests, as well as non-
parametric Mann-Whitney U tests, were performed.
RESULTS
In total, 38 of the 50 children who were treated with AL experi-
enced recurrent infections during the 42-day follow-up.Of these
38 children, 37 had sufficient parasite material to be included in
the analysis.Of the 56 children included in the SP treatment arm,
39 had recurrent infections [2].
In the AL arm, only 2 recrudescences were recorded, which
precluded ameaningful analysis of recrudescence versus reinfec-
tion.Hence, all breakthrough infections in the AL armwere sim-
ply considered to be recurrent and were treated equally. As for
the SP arm, 16 recrudescences were identified. No selection for
either pfcrt or pfmdr1 variants was observed when SP recrudes-
cences were compared with reinfections. These infections were
also grouped together as recurrent infections.
The frequency of parasites carrying the pfcrt K76 allele (in
pure form or mixed with 76T) increased from a baseline preva-
lence of 48.0% to 86.5% (P  .0001) among all recurrent infec-
tions in persons in theAL arm (table 1 andfigure 1) and to 85.7%
(P  .0001) among only reinfections occurring in persons in
the AL arm. A statistically significant selection was also observed
for pfmdr1 N86, which displayed an increase in frequency from
55.9% at baseline to 75.7% among all recurrent infections
(P  .048) (table 1 and figure 1), whereas the frequency in-
creased to 74.3% among only reinfections occurring in the AL
arm (P  .071). The frequencies of the pfmdr1 184F and D1246
alleles remained unaltered (table 1 and figure 1). The SP arm
revealed no changes in the frequency of pfcrt K76T or pfmdr1
N86Y in recurrent infections (table 1). The pfmdr1 1034 and
1042 SNPs, as well as the pfcrt 163 SNPs, showed no variation in
either treatment.
Our sequencing procedures also revealed a novel nonsynony-
mous pfmdr1 W1031R SNP (TGG3CGG) located in a pre-
dicted transmembrane domain [25]. The new SNP, which was
Table 1. Frequencies of the analyzed single-nucleotide polymorphisms (SNPs), both before the administration of the drug
(D0) and in recurrent infections (R0).
Frequency, (pure  mix)/all [95% CI]a
R0
SNP D0 AL SP
pfcrt K76 (2623)/102  0.480 [0.386–0.576] (2210)/37  0.865 [0.716–0.946] (127)/34  0.559 [0.394–0.711]
pfmdr1 N86 (2730)/102  0.559 [0.462–0.651] (217)/37  0.757 [0.597–0.868] (86)/33  0.424 [0.272–0.592]
pfmdr1 184F (025)/100  0.250 [0.175–0.344] (310)/34  0.382 [0.239–0.550] NA
pfmdr1 D1246 (5024)/98  0.755 [0.661–0.830] (219)/35  0.857 [0.702–0.942] NA
NOTE. The D0 data for both treatment arms were pooled at baseline, because no significant differences were found between the 2 groups for
any of the analyzed SNPs. AL, artemether-lumefantrine; CI, confidence interval; NA, not analyzed; SP, sulfadoxine-pyrimethamine.
a “All” denotes the total no. of successful analyses. The 95% CI was determined using the modified Wald method (GraphPad Software;
GraphPad).
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observed in 2 separate PCR amplification and sequencing stud-
ies, was present in 1 infection at baseline but was not detected
among the recurrent infections in the group givenAL. Finally, an
increased number of pfmdr1 gene copies was not detected in any
of the 89 infections noted at baseline or in the 29 recurrent in-
fections noted in the AL treatment arm that were successfully
analyzed in this Tanzanian cohort.
To directly test the contribution of mutant pfcrt to suscepti-
bility to lumefantrine under controlled in vitro conditions, we
assayed P. falciparum lines that had been genetically engineered
to express distinct pfcrt alleles, rather than the endogenous pfcrt
allele in isogenic background. One set was produced in the CQ-
susceptible GC03 line—a progeny of the HB3  Dd2 genetic
cross [26]. This set enabled us to compare clones expressing the
wild-type CQ-susceptible allele (C2GC03), the CQ-resistant Dd2
allele typical of Asian and African CQ-resistant strains (C4Dd2),
and the CQ-resistant 7G8 allele observed in South America, the
Oceanic region, and India (C67G8) [19]. The Dd2 and 7G8 alleles
contain 8- and 5-point mutations (M74I/N75E/K76T/A220S/
Q271E/N326S/I356T/R371I and C72S/K76T/A220S/N326D/I356L),
respectively, compared with the wild-type allele. To test the ob-
served clinical association between the K76T mutation and sus-
ceptibility to lumefantrine, we also assayed clones generated in
the Dd2 and 7G8 lines, which expressed either the parental allele
(C-1Dd2 and C-17G8) or an allele in which the mutant 76T codon
had been replaced with the wild-type K76 codon (known as the
T76K-1Dd2 and T76K-17G8 “back mutant” clones, respectively).
Recombinant clones were assayed in vitro on 5–8 separate occa-
sions, and parental controls (GC03, Dd2, and 7G8) were assayed
on 7–12 separate occasions.
These in vitro assays revealed that CQ-resistant lines withmu-
tant pfcrt alleles carrying the K76T mutation were uniformly
more susceptible to lumefantrine (table 2). C4Dd2 and C67G8, ex-
pressing the 2 most prevalent alleles of mutant pfcrt worldwide,
both showed a35%decrease in lumefantrine IC50 values, com-
pared with C2GC03 (P  .05 and P  .01, respectively, by the
Mann-Whitney U test). The results achieved using the back-
mutant clones demonstrated that the K76T mutation itself is a
large mediator of this increased susceptibility. Both the T76K-
1Dd2 and T76K-17G8 clones were 2-fold less susceptible to lume-
fantrine than were their recombinant counterparts (for both,
P  .01, by theMann-WhitneyU test). In the parental lines, we
also observed substantially lower lumefantrine IC50 values in
Dd2 and 7G8, compared with GC03.
DISCUSSION
Coartem, a fixed formulation of artemether and lumefantrine, is
currently the most successful and widely implemented ACT and
recently has been adopted as first- or second-line chemotherapy
for the treatment of uncomplicatedmalaria by a large number of
national malaria control programs in sub-Saharan Africa [27].
This combination, referred to as “AL” in the present study, has
consistently demonstrated high efficacy. Nevertheless, the high
levels of parasite transmission in most parts of sub-Saharan Af-
rica dictate that reinfectionswill often occur after cessation ofAL
treatment [1–3]. This creates a risk for selection of reinfecting
lumefantrine-tolerant/-resistant parasites after treatment, when
the slowly eliminated lumefantrine remains at subtherapeutic
concentrations. Previous data from some of the investigators
involved in the present study [11]—data subsequently con-
firmed by others [13, 14]—have shown a consistent pattern of
detectable increases in the frequency of drug resistance–associ-
ated pfmdr1 haplotypes among recurrent infections after AL
treatment. Because these recurrent parasites represent reinfec-
tions in all but a few cases, the data have been interpreted as a
lumefantrine-driven selection for variant pfmdr1 alleles.
In the present study, we report significant selection of the pfcrt
K76 allele after AL treatment, which, to our knowledge, repre-
sents the first report of a significant in vivo association of this
gene with an ACT containing an arylaminoalcohol (a group of
drugs that includes lumefantrine, MQ, and HF). This selection
Figure 1. Set of comparisons (conducted using Fisher’s exact test [see Subjects, Materials, and Methods]) between infections at baseline (D0) and
all recurrent infections (R0) concerning the chloroquine resistance transporter gene (pfcrt) K76 allele and the multidrug resistance gene 1 (pfmdr1) N86,
184F, and D1246 alleles. The pfcrt S163 residue, as well as the pfmdr1 S1034 and N1042 residues, had a prevalence of 100% in this setting, as did
single-copy pfmdr1. AL, artemether-lumefantrine; SP, sulfadoxine-pyrimethamine.
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was not observed in our preceding studies, probably because of
the rarity of the K76 allele in Zanzibar [1, 11, 12], as opposed to
the present study site onmainlandTanzania, where50%of the
analyzed infections harbored K76 allele carriers. As discussed
elsewhere [12], the high efficacy of AL precludes the collection of
statistically meaningful numbers of recrudescent parasites for
analysis. Hence, the conclusions of the present study are mainly
considered to be applicable to parasites causing reinfection (i.e.,
formally “lumefantrine-tolerant” parasites, as opposed to
“lumefantrine-resistant” parasites [15]).
The selection for pfcrt K76 in the recurrent infections ob-
served in the present study is consistent with earlier in vitro data
supporting a role for this gene in P. falciparum susceptibility to
arylaminoalcohols. After allele exchange at the pfcrt amino acid
76 position, isogenic clones have been shown to acquire different
susceptibilities to MQ and HF. In the first of these experiments,
exchanging the K76 for 76T (in the CQ-susceptible GC03 back-
ground) increased parasite in vitro susceptibility to MQ by 2- to
3-fold [19]. In a set of reverse experiments, the replacement of
76TwithK76 decreased the susceptibility of the parasites toMQ,
albeit to a lesser extent (1.5- to 2-fold) [20] (table 2). In another
study, P. falciparum lines selected in vitro for HF resistance were
shown to have acquired pfcrt mutations that included S163R,
which was also associated with MQ resistance [22]. Finally, in
vitro development of resistance to CQ in the Sudanese 106/1
clone (which already harbored 7 of the 8 Dd2 pfcrt mutations,
lacking only K76T) resulted in novel pfcrt SNPs at position 76
(K76I/N) [17, 21]. These novel K76I/N SNPs were shown to
significantly increase susceptibility to MQ and HF [21].
Our present research extends these observations by docu-
menting a 2-fold increase in susceptibility to lumefantrine in
parasites expressing the K76T mutation (compare C-1Dd2 with
T76K-1Dd2 and compare C-17G8 with T76K-17G8). Interestingly,
7G8was 2-foldmore susceptible thanDd2, a finding that, on the
basis of our data, cannot be attributed to differences between
these pfcrt alleles. These lines also differ in their pfmdr1 point
mutations (with Dd2 having the 86Y/Y184/S1034/N1042/
D1246 haplotype and with 7G8 having the N86/184F/1034C/
1042D/1246Y haplotype) as well as their copy number (3–4 cop-
ies in our Dd2 line, compared with 1 copy in 7G8). Both types of
genetic changes in pfmdr1 are known to affect susceptibility to
lumefantrine. Other, as yet undefined mediators may also differ
between 7G8 and Dd2. Overall, our data clearly define the pfcrt
K76T mutation as a major determinant that contributes to de-
creased susceptibility to lumefantrine on distinct genetic back-
grounds.
Our results also show that the 2 globally most prevalent mu-
tant pfcrt alleles, Dd2 and 7G8, both increase susceptibility to
lumefantrine (compare C4Dd2 and C67G8 with the isogenic CQ-
susceptible C2GC03 line). In this regard, lumefantrine is an ideal
ACT partner drug in areas of high resistance to CQ. Interest-
ingly, mutant pfcrt alleles have also previously been found to
significantly increase susceptibility to artemisinin [19]. This
finding indicates an important dual benefit of using AL in areas
with a high prevalence of mutant pfcrt conferring resistance to
CQ.
Mutant PfCRT is thought to efflux compounds out of the DV
into the cytoplasm. For CQ, which interferes with the detoxifi-
cation of heme moieties inside the DV, resistance is thought to
be achieved by mutant PfCRT-mediated export of drug away
from its hematin target [25]. CQ resistance has been shown to
critically depend on the pfcrt K76T mutation [20]. The observa-
tion that parasites carrying the pfcrt K76T mutation are more
susceptible to lumefantrine and MQ suggests that those com-
pounds might also be transported by mutant PfCRT out of the
DV and, consequently, might exert their action in the parasite
cytoplasm.
For pfmdr1 and its encodedABC-transporter Pgh-1, transport
studies have shown that the pfmdr1 copy number is associated
with Fluo-4 accumulation inside the DV [28]. Moreover, it has
been shown that the pfmdr1 gene expressed in Saccharomyces
cerevisiae functionally complements an exporter in the plasma
membrane [29], with the nucleotide-binding domains on the
cytosolic side [30]. In the DVmembrane, Pgh-1 is situated with
the nucleotide-binding domains in the cytoplasm [31, 32], indi-
cating a transport direction from the cytoplasm into the DV.
Thus, Pgh-1 may function as a drug importer. For drugs such as
CQ that have their target inside the DV, an increased number of
pfmdr1 copies might therefore be expected to result in increased
drug susceptibility. In line with this hypothesis, selection of
high-level CQ resistance has been observed to result in pfmdr1
deamplification [33]. For drugs that have their target outside the
DV, increased numbers of pfmdr1 copies might therefore result
in decreased susceptibility. The observed association between an
increased pfmdr1 copy number and treatment failures after AL
[8], MQ, or artesunate-MQ therapy [9] is therefore another in-
dication that the target of lumefantrine and MQ might lie out-
side the DV.
The CQ susceptibility markers pfcrtK76 and pfmdr1N86 [18]
and increases in pfmdr1 copy number have all been associated
with a decreased susceptibility to both lumefantrine and MQ
[7–9, 11, 19–21, 34, 35]. Thus, substantial evidence points to
cross-resistance between the 2 arylaminoalcohols. In Southeast
Asia, decreased efficacy of artesunate-MQ treatment has been
reported [36], presumably because of MQ resistance caused by
an increased pfmdr1 copy number [37]. Although an increased
pfmdr1 copy number seems to be rare in Africa, it has previously
been detected in Gabon in a subset of patients treated with a low
dose ofMQ. This suggests a risk for selection and spread of mul-
ticopy pfmdr1 in Africa after the ongoing wide-scale deployment
of AL [10]. This finding, combined with our observation of se-
lection of pfcrt K76 and pfmdr1 N86 alleles, suggests that AL
tolerance or resistance could emerge in Africa. This scenario
would have major public health implications for AL as a malaria
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treatment, in terms of its ability to effectively and sustainably
reduce disease-associated morbidity and mortality.
In the present study, we compared selection of pfmdr1 and
pfcrt mutations that occurred in association with AL treatment
with selection that occurred in association with treatment with
SP, a drug for which resistance is established to be unrelated to
genetic alterations in these genes. Because no selection was ob-
served for the analyzed SNPs in the SP arm, the present study
supports the argument that pfmdr1N86 and, now, pfcrt K76 are
specifically associated with a decreased susceptibility to lume-
fantrine, allowing a more successful reinfection of the human
host in the period corresponding to slowly decreasing lumefan-
trine concentrations [11, 15].
The lack of pfcrt K76 selection in the SP treatment arm is in
apparent contrast to the documented replacement of the 76T
allele by K76 in regions where SP has been introduced to replace
CQ, as has been illustrated by reports from Malawi [38, 39]. In
this regard, we speculate that harboring pfcrt K76 presents a rel-
atively small fitness advantage, compared with harboring pfcrt
76T. In the absence of CQ pressure over several years, the pro-
gressive replacement becomes detectable in the overall popula-
tion, ultimately overtaking the parasite population harboring
the K76T mutation [38–41].
In conclusion, we identified the pfcrt K76 allele as a further
potential marker of decreased susceptibility to lumefantrine in
vivo, in addition to the established pfmdr1 SNPs [10–12]. Im-
portantly, pfcrt encoding the K76Tmutation, which confers CQ
resistance in vitro and is a highly sensitive marker of CQ treat-
ment failure in vivo, also increases in vitro susceptibility to arte-
misinin [19]. These findings highlight a substantial benefit of
using AL in areas with a high prevalence of CQ-resistant P. fal-
ciparummalaria. Defining the interrelationships between drug-
determinant polymorphisms and changes in susceptibility to the
various antimalarials will be important in ongoing efforts to best
manage the implementation of different ACTs and reduce the
dissemination and influence of drug-resistant malaria.
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